PA
BCAX

Parallel Advisors’s Bicara Therapeutics BCAX Stock Holding History

Parallel Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$716 Buy
+36
New +$620 ﹤0.01% 3603

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Parallel Advisors's BCAX Position: Q1 2026 in Review

Parallel Advisors opened a new position in Bicara Therapeutics (BCAX) in Q1 2026: 36 shares worth $716. The stake represents ﹤0.01% of the portfolio and ranks #3603 among its holdings.

146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Parallel Advisors held 36 shares of Bicara Therapeutics worth $716 as of Q1 2026.
  • Bicara Therapeutics was a new Parallel Advisors position in Q1 2026.
  • Bicara Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3603 holding.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.